Drug Profile


Alternative Names: AFQ-056

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Alkynes; Antiparkinsonians; Anxiolytics; Esters; Indoles; Nitriles; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cocaine abuse
  • Discontinued Anxiety disorders; Chorea; Drug-induced dyskinesia; Fragile X syndrome; Gastro-oesophageal reflux; Obsessive-compulsive disorders; Smoking withdrawal

Most Recent Events

  • 04 Dec 2017 Phase-II clinical trials in Cocaine abuse in Spain (PO) (NCT03242928)
  • 14 Nov 2017 Yale University plans an early phase I trial for Alcoholism in USA in November 2017 (NCT03341715)
  • 11 Aug 2017 Novartis plans a phase II trial for Cocaine abuse (NCT03242928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top